Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

  • ID: 4564094
  • Drug Pipelines
  • 576 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adocia SAS
  • BioLingus AG
  • Eli Lilly and Co
  • Kamada Ltd
  • Pfizer Inc
  • Tetragenetics Inc
  • MORE
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of Type1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of Type1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights:

This latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type1 diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 33, 29, 2, 102, 32 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adocia SAS
  • BioLingus AG
  • Eli Lilly and Co
  • Kamada Ltd
  • Pfizer Inc
  • Tetragenetics Inc
  • MORE
Introduction

Type1 diabetes (Juvenile Diabetes) - Overview

Type1 diabetes (Juvenile Diabetes) - Therapeutics Development

Type1 diabetes (Juvenile Diabetes) - Therapeutics Assessment

Type1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development

Type1 diabetes (Juvenile Diabetes) - Drug Profiles

Type1 diabetes (Juvenile Diabetes) - Dormant Projects

Type1 diabetes (Juvenile Diabetes) - Discontinued Products

Type1 diabetes (Juvenile Diabetes) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Cellix Bio Pvt Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by DanDrit Biotech A/S, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Co, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by ImCyse SA, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Just Biotherapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by MannKind Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Maruho Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H1 2018

List of Figures

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adocia SAS
  • AiCuris GmbH & Co KG
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Amarantus Bioscience Holdings Inc
  • Amarna Therapeutics BV
  • apceth Biopharma GmbH
  • Aphios Corp
  • Apodemus AB
  • Arecor Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • Axxam SpA
  • Beta-Cell NV
  • Biocon Ltd
  • BioLineRx Ltd
  • BioLingus AG
  • Biozeus
  • BirchBioMed Inc
  • Boehringer Ingelheim GmbH
  • Boston Therapeutics Inc
  • BTB Pharma AB
  • Caladrius Biosciences Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • Compugen Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dance Biopharm Inc
  • DanDrit Biotech A/S
  • Denceptor Therapeutics Ltd
  • Diabetology (Products) Ltd
  • Diamyd Medical AB
  • Diasome Pharmaceuticals Inc
  • DiaVacs Inc
  • Dompe Farmaceutici SpA
  • Eli Lilly and Co
  • Eloxx Pharmaceuticals Inc
  • Ensol Biosciences Inc
  • EpiVax Inc
  • Evotec AG
  • Fate Therapeutics Inc
  • Generex Biotechnology Corp
  • GeNeuro SA
  • Geropharm LLC
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals Co Ltd
  • ImCyse SA
  • Intrexon Corp
  • Johnson & Johnson
  • Just Biotherapeutics Inc
  • Kadimastem Ltd
  • Kamada Ltd
  • Kasiak Research Pvt Ltd
  • Lexicon Pharmaceuticals Inc
  • MannKind Corp
  • Maruho Co Ltd
  • MedImmune LLC
  • Medtronic Plc
  • Medy-Tox Inc
  • Merck & Co Inc
  • Meridigen Biotech Co Ltd
  • Neovacs SA
  • Novo Nordisk AS
  • Oramed Pharmaceuticals Inc
  • Orgenesis Inc
  • OSE Immunotherapeutics
  • Paras Biopharmaceuticals Finland Oy
  • Parvus Therapeutics Inc
  • Pathfinder Cell Therapy Inc
  • Pfizer Inc
  • PharmaCyte Biotech Inc
  • PharmaIN Corp
  • Pharmasum Therapeutics AS
  • Prometheon Pharma LLC
  • Purzer Pharmaceutical Co Ltd
  • RedHill Biopharma Ltd
  • REGiMMUNE Corp
  • Reliance Life Sciences Pvt Ltd
  • reMYND NV
  • Renova Therapeutics Inc
  • Rezolute Inc
  • Rubius Therapeutics Inc
  • Sanofi
  • Semma Therapeutics Inc
  • Sotio AS
  • Tetragenetics Inc
  • Thermalin Diabetes LLC
  • Toleranzia AB
  • Tolerion Inc
  • Topas Therapeutics GmbH
  • Transgene Biotek Ltd
  • UCB SA
  • Unicyte AG
  • Ventria Bioscience
  • ViaCyte Inc
  • vTv Therapeutics Inc
  • XERIS Pharmaceuticals Inc
  • XL-protein GmbH
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll